Sarah Alwardt, McKesson’s vice president of health informatics and HEOR, says companies should utilize historic real-world evidence in oncological clinical trials.
“If multiple biopharma companies are developing new drugs for the treatment of renal cell carcinoma, and each is conducting trials with nearly identical control groups, the possibility exists for all to draw data from the same control group,” she writes in an article published in OncologyLive. “This may present some risk to the biopharma companies but could be a major boost for patients in the form of faster access to promising new therapies.”
To read the article on OncologyLive, click here. (Paid subscription required)